Wall Street Zen Upgrades Pyxis Oncology (NASDAQ:PYXS) to Hold

Pyxis Oncology (NASDAQ:PYXS) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other analysts also recently issued reports about the company. HC Wainwright upped their price objective on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Royal Bank Of Canada reduced their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. Finally, Stephens raised their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.20.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $1.37 on Friday. The business’s fifty day moving average price is $1.49 and its two-hundred day moving average price is $2.48. The stock has a market cap of $85.30 million, a PE ratio of -0.86 and a beta of 1.45. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.55.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds have recently made changes to their positions in the stock. Maia Wealth LLC purchased a new position in shares of Pyxis Oncology in the 4th quarter worth $25,000. Engineers Gate Manager LP purchased a new stake in Pyxis Oncology during the fourth quarter valued at about $26,000. Fox Run Management L.L.C. acquired a new stake in Pyxis Oncology during the fourth quarter worth about $26,000. Catalyst Funds Management Pty Ltd acquired a new stake in Pyxis Oncology during the second quarter worth about $26,000. Finally, Avanza Fonder AB purchased a new position in shares of Pyxis Oncology in the 4th quarter worth about $31,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.